Review
Oncology
Houssein Chhouri, David Alexandre, Luca Grumolato
Summary: Lung cancer is a leading cause of cancer-related deaths worldwide, and targeted therapies have shown significant improvement in patient outcomes. However, acquired resistance is a common issue leading to tumor relapse. This review discusses the mechanisms of resistance and tolerance to targeted therapy in lung cancer.
Review
Immunology
Can Xu, Menglin Xiao, Xiang Li, Lei Xin, Jia Song, Qi Zhan, Changsheng Wang, Qisong Zhang, Xiaoye Yuan, Yanli Tan, Chuan Fang
Summary: The glioma tumor microenvironment and the role of glioma-associated macrophages (GAMs) in tumor development and response to therapies are reviewed. GAMs, derived from brain-resident microglia or bone marrow-derived monocytes, exert immune functions and affect various biological functions of gliomas. The plasticity of M1 and M2 macrophages under malignant conditions is also discussed, highlighting the potential therapeutic targets of GAMs in glioma therapy.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Medicine, Research & Experimental
Negin Karamali, Samaneh Ebrahimnezhad, Reihaneh Khaleghi Moghadam, Niloofar Daneshfar, Alireza Rezaiemanesh
Summary: In tumor cells, HRD1 plays a crucial role in protein degradation and regulation through pathways such as ERAD. Dysregulation of HRD1 in cancer has significant effects on the development of cancer hallmarks and drug resistance. Thus, it is necessary to study and develop HRD1 as a novel therapeutic strategy in cancer treatment.
Review
Biochemistry & Molecular Biology
Jiajia Wu, Zhenghong Lin
Summary: Precision medicine has expanded treatment options for NSCLC patients through targeted therapy based on genetic and epigenetic cues. Antibodies and inhibitors that target critical gene-mediated signaling pathways have improved patient prognosis. However, resistance due to genetic alterations poses significant challenges in the treatment of metastatic NSCLC patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Lucia Gandullo-Sanchez, Atanasio Pandiella
Summary: By studying resistant clones derived from HER2+ breast cancer cell line, it was found that resistance to T-DM1 was associated with decreased levels of HER2, but the cells still depended on HER2. Antibody array analysis revealed the expression of EGFR in T-DM1-resistant cells, and targeted therapy against EGFR showed an anti-proliferative effect on these cells.
Review
Pharmacology & Pharmacy
Rui-Fang Dong, Miao-Lin Zhu, Ming-Ming Liu, Yi-Ting Xu, Liu-Liu Yuan, Jing Bian, Yuan-Zheng Xia, Ling-Yi Kong
Summary: The article discusses the mechanisms of EGFR-TKIs resistance induced by secondary EGFR mutations, such as T790M and C797S. It highlights the development of targeted drugs to overcome resistance mediated by EGFR mutations.
PHARMACOLOGICAL RESEARCH
(2021)
Article
Medicine, Research & Experimental
Onat Kadioglu, Mohamed E. M. Saeed, Nuha Mahmoud, Shaymaa Azawi, Kristin Mrasek, Thomas Liehr, Thomas Efferth
Summary: The study characterized U87.MG Delta EGFR glioblastoma cells with constitutively active EGFR and identified novel drug resistance mechanisms related to the expression of mutation-activated EGFR. The cells showed numerous chromosomal aberrations and gene overexpression, including well-known drug resistance genes and novel ones. These findings may have important implications for future treatment strategies.
Article
Cell Biology
Christine Parseghian, Madhulika Eluri, Scott Kopetz, Kanwal Raghav
Summary: This article discusses the development of acquired resistance to anti-EGFR therapies, highlighting the predominance of transcriptomic mechanisms of resistance in first-line treatment and acquired MAPK mutations in later-line treatment. It emphasizes the importance of prospective studies guided by acquired MAPK mutations in evaluating anti-EGFR rechallenge strategies.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2023)
Review
Medicine, General & Internal
Bernd Kaina
Summary: This review discusses the mechanisms of genotoxic methylating agents in the therapy of malignant gliomas, including apoptosis, necroptosis, drug-induced senescence, and autophagy. It also explores the resistance mechanisms of glioblastoma to alkylating agents and alternative therapies for overcoming chemoresistance.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Chemistry, Multidisciplinary
Qiujun Qiu, Xinyi Ding, Jixiang Chen, Sunhui Chen, Jianxin Wang
Summary: Gliomas are aggressive and lethal tumors for which there are few treatment options. Nanobiotechnology offers promising strategies for early diagnosis, postoperative regrowth suppression, and microenvironment remodeling. It has the potential to address the challenges of managing recurrent glioma and accelerating drug development.
JOURNAL OF CONTROLLED RELEASE
(2023)
Review
Biochemistry & Molecular Biology
Xueli Tian, Tingxuan Gu, Mee-Hyun Lee, Zigang Dong
Summary: Lung cancer is the most deadly cancer worldwide, with non-small cell lung cancer (NSCLC) being the main type and EGFR as a key driver gene. Despite the effectiveness of EGFR-tyrosine kinase inhibitors in targeted therapy, acquired resistance remains a significant challenge, prompting the exploration of combination treatment options.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
(2022)
Article
Pharmacology & Pharmacy
Elena de las Heras, M. Lluisa Sagrista, Montserrat Agut, Santi Nonell
Summary: This study explores the use of actively-targeted chemo-photo-nanocarriers to improve the localization of chemotherapy drugs in tumor cells. The results show that the attachment of high concentrations of doxorubicin to cetuximab-IRDye700DX-mesoporous silica nanoparticles yields efficient and selective photokilling of EGFR-expressing cells, without any dark toxicity.
Article
Multidisciplinary Sciences
Anna Gogleva, Dimitris Polychronopoulos, Matthias Pfeifer, Vladimir Poroshin, Michael Ughetto, Matthew J. Martin, Hannah Thorpe, Aurelie Bornot, Paul D. Smith, Ben Sidders, Jonathan R. Dry, Miika Ahdesmaki, Ultan McDermott, Eliseo Papa, Krishna C. Bulusu
Summary: Resistance to EGFR inhibitors is a major challenge in the treatment of non-small cell lung cancer. The authors developed a recommender system that ranks genes based on diverse types of evidence, identifying potential mechanisms of EGFR inhibitor resistance.
NATURE COMMUNICATIONS
(2022)
Review
Oncology
Jue Hou, Zongsheng He, Tian Liu, Dongfeng Chen, Bin Wang, Qinglian Wen, Xi Zheng
Summary: Molecular targeted therapy has significantly improved cancer treatment by providing better therapeutic responses and reducing systemic toxicity. However, therapeutic resistance remains a major challenge, hindering the continuous clinical benefits for cancer patients. The recent development of advanced technologies, such as CRISPR-Cas9 screening and patient-derived models, has provided powerful tools to understand the underlying mechanisms of resistance in targeted cancer therapies. This review explores therapeutic targets and the high-throughput CRISPR-Cas9 screening technology, which can uncover potential mechanisms of unresponsiveness and guide the development of next-generation anti-cancer drugs.
FRONTIERS IN ONCOLOGY
(2022)
Review
Chemistry, Multidisciplinary
Qiurong Yang, Jing Xu, Jianmei Gu, Hui Shi, Jiayin Zhang, Jianye Zhang, Zhe-Sheng Chen, Xinjian Fang, Taofeng Zhu, Xu Zhang
Summary: Extracellular vesicles (EVs) play critical roles in cancer progression, including cancer growth, metastasis, and drug resistance. They regulate signaling pathways associated with cancer stemness and autophagy, influencing cancer cells' resistance to chemotherapy and other treatments. Additionally, EVs modulate the interactions between cancer cells and noncancer cells in the tumor microenvironment, leading to therapy resistance.
